Search the Newsreel

Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary

Lipocine Inc. reported its Q2 2026 financial results, with revenue of $190,099 and a net loss of $(2,622,595), resulting in a diluted EPS of $(0.32). Revenue significantly declined year-over-year due to a shift in revenue mix, despite progress in pipeline development and capital raising …

Lipocine Inc. (LPCN) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company. It includes real-time stock price data, historical performance, key financial metrics, an overview of the company's drug pipeline and research focus, and recent analyst insights. The company specializes …

Disc Medicine, Inc. Revenue Breakdown – NASDAQ:IRON

The article provides a financial overview of Disc Medicine, Inc. (NASDAQ:IRON) on TradingView, focusing on its revenue breakdown and other fundamental statistics. It highlights sections for statements, dividends, earnings, and segment performance. The content indicates that the market was closed at the time of …

Here is Why Growth Investors Should Buy Cinemark (CNK) Now

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. That's because, these stocks usually carry above-average risk …

Disc Medicine, Inc. (IRON) Stock Analysis: Exploring a 32% Potential Upside with Strong Buy Ratings

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing therapies for hematologic diseases. Analysts project a 32% potential upside for the stock, with an average target price of $101.00 and 13 strong buy ratings. Despite negative earnings and cash flow, …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares to 29 new non-executive employees on August 3, 2026. These grants were made under the company's 2024 Inducement Plan as material inducements for employment, in accordance with …

CROX or CTAS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Textile - Apparel sector might want to consider either Crocs (CROX) or Cintas (CTAS). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are …

3D Medicines Inc. Announces Change Of Principal Place Of Business In Hong Kong

Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Segall Bryant & Hamill LLC Purchases New Holdings in Cintas Corporation $CTAS

Segall Bryant & Hamill LLC has acquired a new stake of 18,634 shares, valued at approximately $3.15 million, in Cintas Corporation (NASDAQ:CTAS). Cintas reported strong quarterly earnings, exceeding analyst expectations with $1.29 EPS and $2.91 billion in revenue, and subsequently raised its quarterly dividend …

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $2.6 million and detailing progress on its drug candidates. The company provided updates on LPCN 1154 for Postpartum Depression, LPCN 2201 for Major Depressive Disorder, …

Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027

Lipocine Inc. reported a Q2 2026 revenue of $190,099 and a net loss of $2.6 million, with a H1 2026 loss of $6.3 million. Despite increased operating expenses due to higher R&D, the company has extended its cash runway to August 2027 after raising …

Cintas Corporation $CTAS Shares Sold by Bank of America Corp DE

Bank of America Corp DE has reduced its stake in Cintas Corporation (CTAS) by 16% in the first quarter, selling over 254,000 shares but still retaining 1.34 million shares valued at $226 million. Despite this sale, institutional investors and hedge funds collectively own 63.46% …

3 Reasons We’re Fans of Cintas (CTAS)

Cintas (CTAS) is highlighted as a compelling investment due to three key factors: strong revenue growth, excellent free cash flow margins, and stellar return on invested capital (ROIC). The company has demonstrated impressive 9.6% annualized revenue growth over the last five years, boasts an …

Responsive Playbooks and the PRAX Inflection

This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting weak near and mid-term sentiment that contrasts with a positive long-term outlook. The report identifies no clear price positioning signals and notes elevated downside risk. It also provides three AI-generated trading strategies—Position, Momentum Breakout, …

How Robust Q2 2026 Earnings and Buybacks Will Impact Cincinnati Financial (CINF) Investors

Cincinnati Financial Corporation (CINF) reported strong Q2 2026 results with increased revenue and net income, alongside significant share repurchases. These actions reinforce the company's focus on disciplined underwriting, risk management, and capital returns, impacting its per-share results. Investors should consider the ongoing share buybacks …

Lipocine: Q2 Earnings Snapshot

Lipocine earnings beat by $0.12, revenue topped estimates

Lipocine's Postpartum Depression Trial Did Not Meet Primary Endpoint

Vicinity Centres (ASX:VCX) Edges Up—What Investors Typically Look for in Retail REITs

InSilico Medicine (SEHK:3696) Lands FDA Fast Track And Launches AI Drug Benchmarks

PRME|Prime Medicine Inc|Price:2.935|Chg%:+0.125

This article provides a comprehensive stock analysis of Prime Medicine Inc (PRME) from TradingKey, highlighting its "fairly valued" status within the Biotechnology & Medical Research industry. The company, which specializes in gene editing therapies, has significant growth potential, high institutional ownership, and a strong …

InSilico Medicine Cayman TopCo (SEHK:3696) Stock May Be Below Fair Value On FDA Fast Track News

China Cinda Asset Management Issues Profit Warning: Net Profit Expected to Drop 20-25% and Attributable Profit Down 60-70% for H1 2026 1 – Minichart

Cinemark swings into record domestic weekend box office with ‘Spider-Man’

Cinemark Holdings, Inc. achieved its biggest domestic weekend box office ever from July 31-August 2, driven by the opening of "Spider-Man: Brand New Day" and the continued success of "The Odyssey." This new Spider-Man film also set a record for Cinemark's best-ever three-day opening …

Cintas Climbs 15 Spots on Fortune 500 List

Cintas Corporation has advanced 15 places on the Fortune 500 list, now ranking 412th, marking its ninth consecutive year on the prestigious list. The company attributes this progress to its employee-partners and reported $10.34 billion in revenue for FY25, a 7.7% increase from FY24. …

Cintas Corporation Announces Appointment of Jim Rozakis as President and Chief Operating Officer, Effective August 1, 2026

Cintas Corporation has announced the appointment of Jim Rozakis as President and Chief Operating Officer, effective August 1, 2026. This move follows the company's decision to separate the roles of President and Chief Executive Officer. Todd Schneider will continue as the Chief Executive Officer.

nCino, Braze, ServiceNow, Health Catalyst, and Palo Alto Networks Shares Are Soaring, What You Need To Know

Shares of nCino, Braze, ServiceNow, Health Catalyst, and Palo Alto Networks surged due to easing geopolitical tensions, specifically a diplomatic shift with Iran, and increased AI-driven M&A activity. The de-escalation led to lower Treasury yields, which benefits growth-oriented tech equities by reducing discount rates …

/C O R R E C T I O N -- LG Electronics USA/

In the news release, LG ELECTRONICS BRINGS BOB ROSS' CREATIVITY TO LIFE THROUGH MULTIPLE MEDIUMS INCLUDING LG GALLERY+, issued 03-Aug-2026 by LG Electronics USA over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with …

Why Cincinnati Financial (CINF) is a Great Dividend Stock Right Now

Cincinnati Financial (CINF) is highlighted as a strong dividend stock due to its consistent cash flow generation, competitive dividend yield of 2.12%, and a history of dividend increases. The company's current payout ratio is 39%, and it is expected to have solid earnings growth …

Beijing Tong Ren Tang Healthcare Ends IPO Stabilization as Over-Allotment Option Lapses

Lipocine appoints Michael Grissinger to board of directors

Lipocine Inc. has announced the appointment of Michael J. Grissinger to its Board of Directors. Grissinger brings extensive experience from Johnson & Johnson, where he held senior management roles in pharmaceutical licensing, corporate development, and M&A. Lipocine is a biopharmaceutical company focused on oral …

Cinemark (NYSE:CNK) Reaches New 1-Year High on Analyst Upgrade

Cinemark (NYSE:CNK) recently hit a new 52-week high after Weiss Ratings upgraded its stock and several analysts raised their price targets, including Wedbush. The company reported strong quarterly earnings, beating estimates with $1.19 EPS and revenue up 15.5% year over year to $1.09 billion. …

Samson Rock Capital LLP Makes New $2 Million Investment in Cintas Corporation $CTAS

Samson Rock Capital LLP has made a new $2 million investment in Cintas Corporation (NASDAQ:CTAS), acquiring 11,780 shares, which now constitute 4.4% of the fund's holdings. Cintas has exceeded quarterly earnings expectations, reporting $1.29 EPS and $2.91 billion in revenue, and raised its quarterly …

Rathbones Group PLC Lowers Stock Position in Cintas Corporation $CTAS

Rathbones Group PLC reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 12.4% in the first quarter, selling over 72,000 shares but still retaining a significant holding valued at $86.7 million. Despite this reduction, Cintas reported strong financial performance, beating earnings estimates and increasing its …

Does Cintas' (CTAS) Higher Dividend Payout Clarify Its Long‑Term Capital Return Priorities?

Cintas Corporation has approved a higher quarterly cash dividend of US$0.52 per share, reinforcing its commitment to returning capital to shareholders and its strong cash generation. This dividend increase supports the company's investment narrative, which relies on the durability of its recurring uniform and …